Business Description
Exelixis is a US-based cancer treatment company that develops and sells medicines for hard-to-treat cancers, with its core products built around cabozantinib, a compound that targets multiple proteins involved in tumor growth. Its approved treatments address cancers including advanced kidney cancer, thyroid cancer, and melanoma, while a broader pipeline of experimental therapies is currently in development. Founded in 1994 and based in Alameda, California, the company works alongside a wide network of pharmaceutical partners to advance its research and expand the reach of its treatments.
